Free Trial

Travere Therapeutics (TVTX) Competitors

Travere Therapeutics logo
$15.24 +0.75 (+5.18%)
Closing price 04:00 PM Eastern
Extended Trading
$15.24 -0.01 (-0.03%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TVTX vs. AXSM, ADMA, ZLAB, AKRO, PCVX, PTCT, CYTK, RYTM, KRYS, and MRUS

Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), Zai Lab (ZLAB), Akero Therapeutics (AKRO), Vaxcyte (PCVX), PTC Therapeutics (PTCT), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), Krystal Biotech (KRYS), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry.

Travere Therapeutics vs. Its Competitors

Axsome Therapeutics (NASDAQ:AXSM) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

81.5% of Axsome Therapeutics shares are owned by institutional investors. 22.4% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Axsome Therapeutics presently has a consensus target price of $172.33, suggesting a potential upside of 65.29%. Travere Therapeutics has a consensus target price of $32.14, suggesting a potential upside of 110.91%. Given Travere Therapeutics' higher possible upside, analysts plainly believe Travere Therapeutics is more favorable than Axsome Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics
0 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
3.06
Travere Therapeutics
0 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.87

Axsome Therapeutics received 393 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 70.97% of users gave Axsome Therapeutics an outperform vote while only 61.94% of users gave Travere Therapeutics an outperform vote.

CompanyUnderperformOutperform
Axsome TherapeuticsOutperform Votes
489
70.97%
Underperform Votes
200
29.03%
Travere TherapeuticsOutperform Votes
96
61.94%
Underperform Votes
59
38.06%

Axsome Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Axsome Therapeutics has higher revenue and earnings than Travere Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome Therapeutics$385.69M13.31-$287.22M-$5.77-18.07
Travere Therapeutics$273.53M4.95-$321.55M-$2.81-5.42

In the previous week, Axsome Therapeutics had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 9 mentions for Axsome Therapeutics and 6 mentions for Travere Therapeutics. Axsome Therapeutics' average media sentiment score of 0.28 beat Travere Therapeutics' score of 0.11 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Axsome Therapeutics
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Travere Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Axsome Therapeutics has a net margin of -64.39% compared to Travere Therapeutics' net margin of -82.88%. Axsome Therapeutics' return on equity of -272.80% beat Travere Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Axsome Therapeutics-64.39% -272.80% -36.69%
Travere Therapeutics -82.88%-1,179.73%-41.10%

Summary

Axsome Therapeutics beats Travere Therapeutics on 15 of the 19 factors compared between the two stocks.

Get Travere Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TVTX vs. The Competition

MetricTravere TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.35B$2.84B$5.41B$8.72B
Dividend YieldN/A2.69%5.38%4.23%
P/E Ratio-5.4221.5725.7719.53
Price / Sales4.95283.45399.53109.48
Price / CashN/A40.9225.4426.73
Price / Book20.057.438.005.72
Net Income-$321.55M-$55.10M$3.15B$248.44M
7 Day Performance8.16%1.41%2.36%2.33%
1 Month Performance-3.79%8.44%7.18%5.79%
1 Year Performance95.64%-1.35%38.58%16.82%

Travere Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TVTX
Travere Therapeutics
2.3472 of 5 stars
$15.24
+5.2%
$32.14
+110.9%
+98.2%$1.35B$273.53M-5.42460
AXSM
Axsome Therapeutics
4.7055 of 5 stars
$101.69
-2.3%
$172.33
+69.5%
+33.1%$5.01B$432.16M-16.98380Insider Trade
ADMA
ADMA Biologics
3.5393 of 5 stars
$20.40
-2.0%
$24.25
+18.9%
+62.5%$4.87B$459.38M72.86530
ZLAB
Zai Lab
2.2754 of 5 stars
$40.63
-0.9%
$47.37
+16.6%
+93.9%$4.48B$418.33M-14.671,950Insider Trade
AKRO
Akero Therapeutics
3.604 of 5 stars
$55.75
+0.2%
$82.50
+48.0%
+132.9%$4.44BN/A-14.8730
PCVX
Vaxcyte
3.017 of 5 stars
$34.33
-0.7%
$136.50
+297.6%
-55.6%$4.43BN/A-7.46160Positive News
PTCT
PTC Therapeutics
4.5916 of 5 stars
$51.87
+1.2%
$63.75
+22.9%
+35.8%$4.06B$1.77B-8.731,410
CYTK
Cytokinetics
4.2391 of 5 stars
$33.78
-1.7%
$70.92
+110.0%
-39.0%$4.03B$19.22M-6.28250
RYTM
Rhythm Pharmaceuticals
4.1171 of 5 stars
$62.39
-0.8%
$76.62
+22.8%
+48.4%$3.97B$136.86M-14.41140Positive News
KRYS
Krystal Biotech
4.5125 of 5 stars
$133.04
-2.9%
$211.13
+58.7%
-21.1%$3.84B$333.45M44.49210News Coverage
Positive News
Analyst Forecast
MRUS
Merus
3.1724 of 5 stars
$53.30
-2.4%
$85.83
+61.0%
-3.8%$3.78B$54.73M-13.4937

Related Companies and Tools


This page (NASDAQ:TVTX) was last updated on 6/24/2025 by MarketBeat.com Staff
From Our Partners